Similarly to metallic [89Zr]-radiolabeled compounds, 68Ga-based radiopharmaceuticals (Table S1) are used for targeting human epidermal growth factor receptors (HER2) [182] and carcinoembryonic antigen (CEA), which is highly increased in certain types of cancer, but also in benign conditions. This evidence concerns the gene ERBB2 and cancer.